Genferon Light supp 125000ME #10
- 3 or more $16.68
- Availability:In Stock
Genferon Light user manualReed more and buy Genferon LightSee also - Genferon.CompositionThe composition of the suppository for rectal or nasal administration:1 suppository includes: interferon recombinant human alfa-2b-250,000 IU..
Genferon Light user manual
Reed more and buy Genferon Light
See also - Genferon.
The composition of the suppository for rectal or nasal administration:
1 suppository includes: interferon recombinant human alfa-2b-250,000 IU or 125,000 IU (depending on dosage), taurine 5.0 mg.
Excipients: macrogol 1500, polysorbate 80, citric acid, emulsifier T2, solid fat, dextran 60000, sodium citrate, purified water - the amount necessary to obtain a candle weighing 0.8 g.
Spray formulation for nasal application:
One dose of the drug contains: interferon recombinant human alpha-2b - 50 000 ME, taurine - 1.0 mg.
Excipients: dextran 40000, disodium edetate dihydrate, sodium chloride, potassium dihydrogenphosphate, potassium chloride, polysorbate 80, glycerol, methylparahydroxybenzoate, sodium hydrophosphate dodecahydrate, peppermint oil, water for injection in the required amount.
Form of issue
Suppositories of white or straw color. They have a cylindrical shape, a pointed end, are uniform on the longitudinal section, but air inclusions are allowed. Produced in cardboard packs, inside one such pack of 1 or 2 contour packs containing 5 suppositories each.
For nasal spray:
Light transparent liquid in bottles of darkened glass, in the upper part equipped with a dispenser with a safety cap; in a cardboard bundle one such bottle. 1 bottle contains 100 doses.
The pharmacological action of the drug Genferon Light is due to the presence of alfa-2b and taurine in the interferon. They have the following properties:
immunomodulating action (harmonization of immunity functions);
antiproliferative action (inhibition of reproduction of bacteria and cancer cells);
immunostimulating action (improving the effectiveness of immunity);
mediated antimicrobial action;
Pharmacodynamics and pharmacokinetics
The main active substance of Genferon Light is interferon alfa-2b. It was obtained by modification of the bacterium Escherichia coli by means of genetic engineering.
Interferon is able to indirectly influence intracellular pathogens (chlamydia and viruses), altering the metabolism of the cell and stopping their intracellular replication and further spreading. Interferon also affects neighboring cells, initiating reactions that lead to inhibition of the production of viral proteins. The effect of interferon on neighboring cells is to enhance the synthesis of substances that reduce protein synthesis. This mechanism is disastrous for the virus, because blocks its further reproduction. In addition, interferon activates a number of genes that play an important role in the antiviral defense of cells, and triggers the mechanism of death of the infected cell.
Another area of action of interferon is the activation of immunity. The result of this activation is a more effective fight of immune system cells (T-killers, phagocytes and T-helpers) with viruses and bacteria.
Taurine improves the metabolism of individual cells and tissues in general, stimulates reparative (regenerative) processes. It improves and stabilizes the structure of cell membranes. Taurine is an antioxidant - interacting with active compounds of oxygen in the body, it prevents tissue damage by these compounds.
For rectal administration of the drug, a bioavailability of up to 80% or more is characteristic, with which a pronounced local and complex immunomodulatory effect is associated. For vaginal application, a pronounced local (high drug concentration is achieved in the pathological focus) and a minor systemic effect (the drug practically does not penetrate the bloodstream through the mucous membranes of the internal genital organs). As a result, a pronounced local antiviral, antiproliferative and antibacterial action is achieved.
Interferon reaches its maximum concentration in the blood 4-6 hours after administration. It is excreted mainly by the kidneys. The half-life is about 12 hours, which results in the need for a twice-daily drug.
Intranasal use is characterized by a pronounced immunostimulating and antiviral effect (due to a high concentration in the pathological focus). The injection of the drug into the bloodstream at this route of administration does not reach large values because of the special molecular structure of the membranes of the cells of the mucous nasopharynx. However, some amount of interferon nevertheless enters the blood, causing a complex immunomodulating effect.
Indications for use
Genferon Light in the form of Suppositories is part of complex therapy and is used in the prevention of the following diseases in adults and children:
Genferon Light in the form of a nasal spray is used to prevent and treat viral respiratory diseases.
Contraindications when using Suppositories Genferon Light:
individual sensitivity to interferon or other substances in the formulation;
the first 12 weeks of pregnancy;
epilepsy or other convulsive conditions;
severe cardiac conditions;
In patients suffering from autoimmune diseases (Hashimoto's thyroiditis, systemic lupus erythematosus, etc.) or allergic attacks in the past, Genferon Light's Suppositories should be used under close supervision and supervision.
Contraindications when using nasal spray Genferon Light:
individual sensitivity to interferon or other substances in the formulation;
age to 14 years.
With caution should be used in patients with prone to nosebleeds.
Usually, Genferon Light in the form of Suppositories is well tolerated by the sick. There may be a local (at the injection site) itching or burning. These symptoms disappear within three days after discontinuation of the drug. For continuation of treatment it is better to consult with the attending physician.
Systemic reactions such as fever, fever, fatigue, impaired appetite, muscle, joint and headaches, as well as a decrease in the number of leukocytes and platelets in the blood can be observed. But these reactions occur more often when the total dose is exceeded to 10,000,000 IU per day.
When using the spray of Genferon Light, no side effects were observed.
Instructions for use
To rule out the likelihood of overdose or occurrence of side effects on Suppositories by Genferon Light, the instruction instructs children under 7 years to use only 125,000 IU Suppositories. For children older than 7 years, the recommended dosage is 250 thousand IU. It is also worth noting that it is unacceptable to simultaneously use drops in the nose (for treating catarrhal phenomena of the nasal cavity) and nasal spray Genferon Light, the instruction for use warns of possible ineffectiveness of drugs in case of non-compliance with the rules for separate administration. For the treatment of pregnant women with terms of 13-40 weeks, the use of suppositories with a dosage of 250,000 IU is recommended.
Recommended treatment regimens
ARVI, influenza and other acute viral diseases in children: 1 candle rectally every 12 hours as an adjunct to the main treatment for 5 days. If the symptoms do not disappear, it is possible to prolong treatment after a five-day break.
Chronic viral diseases in children: 1 candle rectally twice a day as a supplement to the main treatment for 10 days. Then within 5-15 weeks - 1 candle every other day in the evening.
Acute diseases of the genitourinary system of infectious nature in children: 1 candle rectally twice a day for 10 days.
Diseases of the genitourinary system of an infectious nature in pregnant women: 1 candle rectally twice a day for 10 days.
Diseases of the genitourinary system of an infectious nature in women: 1 candle 250,000 IU twice a day for 10 days (vaginally or rectally). With prolonged course of the disease, it is possible to apply 1 candle every other day in the evening for 5-15 weeks.
Spray Genferon Light is used by inserting into the nasal cavity of the tip of the vial and one short push on the dispenser.
When the flu or SARS begins, apply one dose in both nasal passages three times a day for 5 days (the total daily dose should not be more than 500,000 IU).
To prevent acute respiratory viral infection or influenza (in contact with infected ones) and after hypothermia, it is recommended to adhere to the following scheme of taking the drug: one dose in both nasal passages twice a day for 6-7 days.
Instructions for use of nasal spray.
remove the protective cap;
when used for the first time, press the dispenser repeatedly until a small jet appears;
Before use, give the bottle an upright position;
make the introduction of the drug with a single short pressure on the dispenser in turn in both nasal passages;
after use, close the protective cap.
To prevent the spread of infection, use the bottle strictly individually.
At simultaneous accidental introduction of a large number of suppositories (in doses exceeding prescribed), it is necessary to stop using the drug for one day, then you can resume treatment again according to the prescribed scheme.
There are no data on cases of an overdose of Genferon Light spray.
Presence vitamins C and E increase the action of interferon components and slow down its denaturation when the drug is administered to the rectum.
The drug is advised to keep out of reach of children, dry and dark place in the temperature range of 2-8 ° C.
Shelf life - 24 months. It is not recommended to use the product after the expiration date (indicated on the package).
Genferon Light does not influence the reaction and the possibility of performing actions requiring increased attention (driving, equipment, etc.).
It should be noted that nasal spray is not recommended for use in children under 14 years of age.
Suppositories for children have no age restriction.
The drug can be used for the prescription of a doctor in preterm and newborn children at a dosage of 125,000 IU, if necessary (pneumonia, meningitis, sepsis).
The joint use of Genferon Light in the form of suppositories with antibacterial, antiviral and antifungal agents markedly increases the effectiveness of therapy.
Genferon Light during pregnancy
Use of Genferon Light "nasal spray" during pregnancy is possible at all times, and reviews about its use are, in general, approving.
Safety of the use of Suppositories has been proved only in pregnant women with terms of 13-40 weeks, while in women earlier in pregnancy there is no safety data. In each clinical case, the question of the use of Genferon Light is decided separately by the attending physician.
Reviews of Genferon Light
Positive feedback on Candlelight Suppositories used by Genferon Light in the treatment of infectious diseases of the genitourinary tract. It is important for both children and adults to learn about the absence of reports of side effects.
Information on the practice of using the gene spray Genferon Light in influenza and ARVI often also indicate its high effectiveness.